Evidence map›Paper›PMID 26847337›Full record

ArticleWorld journal of urology2016

Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.

Saeed Dabestani, Andreas Thorstenson, Per Lindblad, Ulrika Harmenberg, Börje Ljungberg, Sven Lundstam

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 7 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 7 syntheses or guidelines pooled it, 284 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Saeed DabestaniDepartment of Urology, Skåne University Hospital, 205 02, Malmö, Sweden.
Andreas ThorstensonSection of Urology, Department of Molecular Medicine and Surgery, Karolinska Institute, 171 64, Solna, Stockholm, Sweden.
Per LindbladDepartment of Urology, Faculty of Medicine and Health, Örebro University, 701 85, Örebro, Sweden.
Ulrika HarmenbergDepartment of Oncology, Karolinska University Hospital, 171 64, Solna, Stockholm, Sweden.
Börje LjungbergDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, 901 85, Umeå, Sweden. borje.ljungberg@umu.se.
Sven LundstamDepartment of Urology, Sahlgrenska University Hospital, 413 45, Gothenburg, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEÖrebro University · SESahlgrenska University Hospital · SESkåne University Hospital · SEUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo present the occurrence of metastases and local recurrences in primary non-metastatic patients with renal cell carcinoma (RCC) in a contemporary Swedish population-based cohort.

methodsBetween 2005 and 2009, a total of 4527 patients were included in the prospective National Swedish Kidney Cancer Register accounting for nearly all RCC patients in Sweden. Among M0 patients, 472 (13 %) had no follow-up data registered within 5-year follow-up time and were excluded from the analysis.

resultsIn total, 939 (21 %) had distant metastases at presentation with a decrease from 23 to 18 % during the inclusion period. Of 3107 patients with follow-up data and with M0 disease, 623 (20 %) were diagnosed with a tumor recurrence during 5-year follow-up. Mean time to recurrence was 24 months (SD ± 20 months). Among these, 570 patients (92 %) were at primary diagnosis treated with radical nephrectomy, 23 patients (3.7 %) with partial nephrectomy and 12 patients (1.9 %) with minimally invasive treatments. The most frequent sites of metastases were lung (54 %), lymph nodes (22 %) and bone (20 %). The treatment of recurrence was in 50 % systemic treatments, while metastasectomy was performed in 17 % of the patients, out of which 68 % were with a curative intention.

conclusionsIn this population-based study, 21 % of the patients had metastatic disease at presentation, with a decreasing trend over the study period. During 5-year follow-up, 20 % of the primary non-metastatic patients had recurrent disease. Of the patients with recurrence, half were given systemic oncological treatment and 17 % underwent metastasectomy.

Indexed as

AdolescentAdultAgedAged, 80 and overCarcinoma, Renal CellChildFemaleFollow-Up StudiesHumansKidney NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesSwedenYoung AdultLocal recurrenceMetastasesMinimal invasive therapyNephrectomyPartial nephrectomyRecurrent diseaseRenal cell carcinomaSurgery

Identifiers

PMID26847337
OpenAlexW2264794294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.